Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21064053 | 0.98 | TSHR (0.35) | MAPK1NPSR1TSHRCYP2C19CYP4F2 | |
| SCHEMBL18361332 | 0.98 | TSHR (0.35) | MAPK1NPSR1TSHRCYP2C19CYP4F2 | |
| SCHEMBL21064071 | 0.98 | TSHR (0.35) | MAPK1NPSR1TSHRCYP2C19CYP4F2 | |
| SCHEMBL18361370 | 0.98 | TSHR (0.35) | MAPK1NPSR1TSHRCYP2C19CYP4F2 | |
| SCHEMBL22874559 | 0.98 | TSHR (0.35) | MAPK1NPSR1TSHRCYP2C19CYP4F2 | |
| SCHEMBL3296871 | 0.98 | TSHR (0.35) | MAPK1NPSR1TSHRCYP2C19CYP4F2 | |
| SCHEMBL4499031 | 0.96 | MAPK1 (0.33) | MAPK1CYP4F2CYP4A11DGAT1GRIN2B | |
| Formic Acid SCHEMBL27634168 | 0.92 | GRIN2B (0.31) | GRIN2BGRIN2C | |
| SCHEMBL2312894 | 0.91 | MAPK1 (0.34) | MAPK1CYP4F2CYP4A11DGAT1 | |
| Formic Acid SCHEMBL27546066 | 0.91 | TSHR (0.31) | TSHRCYP2C19GRIN2BGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-9636409-B2 | Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-05-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CHROMA THERAPEUTICS LTD. (GB) | 2014-03-27 | — | — | US | disclosed |
| US-20140038822-A1 | USE OF SUBSTITUTED SPIROCYCLIC SULFONAMIDOCARBOXYLIC ACIDS, CARBOXYLIC ESTERS THEREOF, CARBOXAMIDES THEREOF AND CARBONITRILES THEREOF OR SALTS THEREOF FOR ENHANCEMENT OF STRESS TOLERANCE IN PLANTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| CN-101959534-B | Enzyme and receptor modulation | CHROMA THERAPEUTICS LTD | 2013-11-27 | — | — | CN | disclosed |
| US-6479518-B2 | PSYCHOLOGICAL DISORDERS | MERCK & CO., INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020120146-A1 | N-cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2002-08-29 | — | — | US | disclosed |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | MERCK & CO., INC. | 2002-04-11 | — | — | US | disclosed |
| EP-1192133-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Merck & Co., Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002024629-A1 | ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-03-28 | — | — | WO | disclosed |
| US-6358979-B1 | FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-03-19 | — | — | US | disclosed |
| US-20020016492-A1 | Process for preparing 3-hydroxymethyl-4-(aryl or heterocyclic)-cyclopentanones | MERCK SHARP & DOHME CORP. | 2002-02-07 | — | — | US | disclosed |
| WO-2000076972-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| EP-0495822-A1 | CARBOXYALKYL DIPEPTIDE INHIBITORS OF ENDOPEPTIDASES | SCHERING CORPORATION (US) | 1992-07-29 | — | — | EP | disclosed |
| WO-1991005796-A1 | CARBOXYALKYL DIPEPTIDE INHIBITORS OF ENDOPEPTIDASES | SCHERING CORPORATION (US) | 1991-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088159-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | MAPK1 3518/4885NPSR1 366/4885TSHR 549/4885 |
| US-20020042431-A1 | Zwitterionic tachykinin receptor antagonists | NPY5R, NPY1R, NPY2R | MAPK1 1015/4885NPSR1 4/4885TSHR 241/4885 |
| US-20160151509-A1 | ENZYME AND RECEPTOR MODULATION | CES1, GLRB, GLRA1 | MAPK1 3518/4885NPSR1 366/4885TSHR 549/4885 |
| US-20020016492-A1 | Process for preparing 3-hydroxymethyl-4-(aryl or heterocyclic)-cyclopentanones | CCR1, CCR5, CCR6 | MAPK1 2014/4885NPSR1 770/4885TSHR 4586/4885 |
| US-20140038822-A1 | USE OF SUBSTITUTED SPIROCYCLIC SULFONAMIDOCARBOXYLIC ACIDS, CARBOXYLIC ESTERS THEREOF, CARBOXAMIDES THEREOF AND CARBONITRILES THEREOF OR SALTS THEREOF FOR ENHANCEMENT OF STRESS TOLERANCE IN PLANTS | STS, SCLY, TST | MAPK1 1454/4885NPSR1 1683/4885TSHR 3078/4885 |
| US-20020120146-A1 | N-cyclopentyl modulators of chemokine receptor activity | CCR1, CCR3, CCR5 | MAPK1 1496/4885NPSR1 97/4885TSHR 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.